Michail Ignatiadis, MD, PhD, Jules Bordet Institute, Brussels, Belgium, shared results from the phase 3 ALEXANDRIA/Impassion030 trial. This interim analysis found the addition of atezolizumab to adjuvant chemotherapy was unlikely to provide a benefit in invasive disease-free survival among patients with triple-negative breast cancer.

Dr Ignatiadas stated, "We believe that this is an important study and that together with the KEYNOTE-522, it can help us understand how to best use immunotherapy in early triple negative breast cancer.”

Transcript:

My name is Michael Ignatiades. I'm director of the Breast Medical Oncology Clinic and Program at the Jules Borde Institute in Brussels, Belgium. I would like to discuss with you today the results of the ALEXANDRIA/IMpassion030 trial. In triple negative breast cancer, optimizing treatment options is an unmet medical need since this is an aggressive subtype. We do know that the current standard of care in early triple negative breast cancer is neoadjuvant chemotherapy and immunotherapy. It is not clear what is the role of adjuvant immunotherapy in patients that get primary surgery for early triple negative breast cancer.

To that end, we have conducted the ALEXANDRIA/IMpassion030 trial, a large, global, phase 3 study, that randomized patients with stage 2 or 3 triple negative breast cancer that have
been operated on to either adjuvant atezolizumab plus chemotherapy versus chemotherapy
alone. Primary endpoint was invasive disease-free survival.

The outcome of this study in this interim analysis was that invasive disease-free survival was not Improved by the addition of atezolizumab. The hazard ratio was 1.12. Based on the study statisticians, the results will not change in the final analysis, so this is a negative study. The safety profile of atezolizumab was in line with side effects observed in the neoadjuvant setting in the IMpassion031 trial, across indications.

We believe that this is an important study that together with the KEYNOTE-522, can help us understand how to best use immunotherapy in early triple-negative breast cancer.

Source:

Ignatiadis M, Bailey A, McArthur H, et al. Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial. Presented at San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, Texas. Abstract GS01-03